aerial mycelium. The cultural characteristics are shown in Table 1 , and the physiological characteristics which include the system of Gordon et al.p are given in Table 2 . Asporogenic variants, which lack the ability to form aerial mycelium, occur after repeated transfers or during long storage. An asporogenic variant, No. N806-4-V7 maintains the ability to produce all components of antibiotic karnamicin. The presence of mesodiaminopimelic acid, ribose, glucose, galactose, rhamnose and mannose in the whole cell hydrolysate of strain No. N806-4 indicates that the strain belongs to cell wall Type III and sugar pattern C. The strain has Type PII phospholipid (presence of phosphatidylethanolamine and phos- and contains MK-9(H4) as the major menaquinone. Glycolate test is negative. Mycolic acid is absent.
The morphology, cultural characteristics and cell chemistry of strain No. N806-4 place it in the genus Saccharothrix,2) in which two species, Saccharothrix australiensis^and S. aerocolonigenes2'>4) have been described. S. australiensis is different from strain No. N806-4 in the following characteristics; the formation of light brownish gray aerial mycelium and dark brown vegetative mycelium in ISP medium No. 2, and clear difference in Gordon's physiological tests. Among the known strains of S. aerocolonigens, only strain C38383 (ATCC39243) which is a rebeccamycin-producing organism, forms spore chains on the aerial mycelium.5) Morphologically, strain No. N806-4 is related to S. aerocolonigenes strain C38383. In addition, strain No. N806-4 is similar to strain C38383and other strains of S. aerocolonigenes in the physiological characteristics of Gordon's tests.0 Thus, strain Observation after incubation at 28°C for 3 weeks. Color name used : ISCC-NBSColor-Name Charts. meyer flask containing 100 ml of the seed medium consisting of soluble starch 0.5 %, glucose 0.5 %, fish meat extract (Mikuni) 0.1 %, yeast extract (Oriental) 0.1 %, NZ-case (Sheffield) 0.2 %, NaCl 0.2 % and CaCO30.1 %. Shake cultivation was carried out at 28°C for 4 days on a rotary shaker (200 rpm). The seed culture (2 ml) was inoculated into a 500-ml Erlenmeyer flask containing 100 ml of fermentation medium composed of mashed potato (Snow Milk Products) 4%, corn steep liquor 2%, NaCl 0.2% and CaCO30.3 % (pH 7.2 before autoclaving). The fermentation was carried out on a rotary shaker (200 rpm) at 28°C for 8 days. The antifungal activity was determined by the conventional broth dilution method in Sabouraud dextrose mediumwith a 96-well microtiter plate using Candida albicans A9540 as the indicator organism. The turbidity was determined by Titertek Multiskan MCC (Flow Laboratories) at 540 nmand HPLCwas also used in parallel with the bioassay. The antifungal activity of the flask fermentation reached a maximumon the 6th day at a concentration of 200^g/ml. Tank fermentation was also carried out. The seed culture was prepared by the sameprocedure as the flask fermentation using the following seed medium, glucose 2 %, soybean meal 1 % and CaCO3 0.5 %. After cultivation on a rotary shaker at 28°C for 4 days, the seed culture (2 liters) was inoculated to a 200-liter tank fermentator which contained 120 liters of the fermentation mediumhaving the Detection: UVabsorption at 254 nm. mm), and developed with a mixture of acetonitrile -0.15% KH2PO4,pH 3.5 (36 :64). Karnamicin A complex was eluted first followed by karnamicin B2, a mixture of karnamicins Bl5 B2 and B3 and then karnamicins C and D complex. Each fraction was concentrated in vacuo and extracted with ethyl acetate for desalting. Repetition of the chromatography for the remaining crude karnamicin complex yielded karnamicin A complex (2.4 g), semi-pure karnamicin B2 (3.4 g), karnamicin B complex (2.0 g) and karnamicins C and D complex (1.6 g) from the crude karnamicin complex (16.8 g).
Purification of Karnamicin A Complex Karnamicin A complex (2.3 g) was chromatographed on a column of LiChroprep RP-18 (22 x 450 mm)eluting with acetonitrile -0.15% KH2PO4,pH 3.5 (33.3 : 66.7). Upon monitoring the eluate by HPLC,a mixture of karnamicins Ax and A2 was eluted first followed by nearly homogeneous karnamicin As. The relevant fractions were concentrated and extracted with ethyl acetate. Evaporation of the extracts gave semi-pure karnamicins Ax and A2 mixture (601 mg) and karnamicin A3 (984 mg). The karnamicins A1 and A2 mixture (550 mg) was re-chromatographed on a column of YMCGEL ODSA60 (Yamamura Chemical Lab., 22 x450 mm). Elution was carried out with methanol -0.03 m phosphate buffer, pH 7.0 (48 : 52). The first active fractions containing homogeneous karnamicin Ax were pooled, concentrated and then extracted with ethyl acetate. Evaporation of the extract yielded a white solid of karnamicin Ax (41 mg). The second active fractions were similarly worked up to give pure karnamicin A2 (118 mg). The solid of karnamicin A3 (705 mg) was further purified by a column of YMCGELODSA60 (22x450mm) using methanol-0.03 m phosphate buffer, pH 7.0 (50 : 50). After examination of the eluates by HPLC,the heart-cuts of karnamicin A3 fractions were concentrated in vacuo to removemethanol. Extraction of the aqueous concentrate with ethyl acetate followed by concentration of the extract afforded pure karnamicin A3 (123 mg).
Purification of Karnamicin B Fraction
The semi-pure karnamicin B2 (47 mg) was purified by preparative HPLCwith a SSC-ODS-842 column (Senshu Kagaku, 30x250 mm). The elution was carried out with a mixture of methanol and 0.03 m phosphate buffer, pH 7.0, 54:46 from 0~15 minutes, a linear gradient 54:46^65 :35 from 15 to 80 minutes, 65 : 35 from 80 to 100 minutes at flow rate of 12.0ml/minute. The eluates were monitored by UVabsorption at 280 nm. Karnamicin B2 was eluted at the retention time of 47 minutes followed by karnamicin B2 at 58 minutes and then karnamicin B3 at 72 minutes. The appropriate eluates were pooled, concentrated and desalted by Diaion HP-20 chromatography. Repetition of the preparative HPLCfor the remaining semi-pure karnamicin B2 yielded pure karnamicin B: (22 mg), karnamicin B2 (230 mg) and karnamicin B3 (15 mg) from the semi-pure solid (568 mg). Karnamicin B complex (750 mg) was purified by preparative HPLCas described above to yield pure karnamicin Bx (54 mg), karnamicin B2 (55 mg) and karnamicin B3 (204 mg). Karnamicin Bx (44 mg) was crystallized from hexane -chloroform to give colorless needles (9 mg), while colorless rods (22 mg of karnamicin B2 and 30 mg of karnamicin B3) were obtained from chloroform by crystallization of karnamicin B2 (52 mg) and karnamicin B3 (48 mg ethanol, but insoluble in «-hexane and water. They gave positive response to Dragendorff and Rydon-Smith reagents, but negative response to Erhlich, Sakaguchi and ninhydrin reagents. Their UVabsorption maxima are located at 219, 242 and 317 nm in methanol and acidic methanol and shifted to 220, 252, 293 and 342 nm in alkaline methanolic solution. Karnamicins Al9 A2, A3 and C5, which have a-hydroxyalkyl side chain on the thiazole ring, exhibited absorption maxima at 220, 251, 281 and 342 nm in alkaline solution. The UV spectrum of karnamicin B2 is shown in Fig. 5 . Their IR spectra exhibited in commonthe presence of amide at 1660^1680 cm"1. The spectra of karnamicins Bl9 Q, D2 and D4 had an additional carbonyl absorption at 1705~1710 cm'1 which is attributed to the ketone carbonyl group in the alkyl chain. The IR spectra of karnamicins Bx and B2 are shown in Figs. 6 and 7, respectively. Figs. 8 and 9 show the *H and 13C NMRspectra of karnamicin B2, respectively. Karnamicin components have the same thiazolylpyridinecarboxamide nucleus and differ from each other in the alkyl side chain moiety. As reported in a separate paper, the structures of all 15 components of karnamicin have been determined by X-ray crystallography and spectral data (Fig. 10) .
Biological Activity The in vitro antifungal activity of the components of karnamicin was determined against various fungi by serial broth and agar dilution methods. Sabouraud dextrose broth and agar were used for the above experiments. The inoculum size was adjusted to 104~106 and 105~109cfu/ml for broth and agar methods, respectively. After incubation at 28°C for 48 or 72 hours, the MIC, the lowest concentration of antibiotic causing virtually complete inhibition of growth, was determined. As shown in Tables 5 and 6 , all components of karnamicin exhibited significant in vitro antifungal activity against C. albicans, Aspergillus fumigatus and Trichophyton mentagrophytes in the broth dilution method, and also showed moderate antifungal activity against various clinically important pathogenic fungi in Sabouraud dextrose agar. The morphological change-inducing activity of karnamicin components was examined with a mutant of C. albicans A9540. The mutant, C. albicans A9540-2 does not form pseudomycelium whenserum is added to the culture media, while the parent strain forms pseudomycelium in the culture condition. Nopseudomycelium formation is observed for both strains cultivated in the media without serum. The suspension of the mutant strain (104 cfu/ml) and each component of karnamicin was incubated for 72 hours at 37°C in Eagle's minimumessential mediumsupplemented with 10% calf serum. The inhibitory activity of karnamicin components against fungal growth was determined by the turbidity described above. Furthermore, morphological change of the mutant strain was obserbed microscopically. Table 7 . Inhibitory and pseudomycelium-inducing
The results are shown in Values in parenthesis indicate partial inhibition.
pseudomycelium-inducing effect against a yeast- nystatin. Groups of 5 female mice (ICR, 182 1 g) were treated subcutaneously with 0.5 mg of estradiol benzoate 3 days before and 4 days after C. albicans A9540 vaginal infection. A cell suspension (0.01 ml) of C. alhicans containing 108 cfu/ml was inoculated intravaginally on day-0. Then, 0.02 ml of the compound dissolved in Solbase (1 : 1 mixture of polyethyleneglycol 400 and polyethyleneglycol 4000, Dainippon Pharmaceutical Co., Ltd.) was instilled intravaginally once a day on days 0 to 4. On day-7, vaginal exudate was taken by a thin glass rod and spread on the YGPagar plate containing yeast extract 0.2%, glucose 1.5 %, peptone 0.5 %, K2HPO40.05%, MgSO4-7H2O0.05% and agar 1.5%. Viable cell count was made after incubation for 2 days at 28°C. The EC50 value, which is the drug concentration (%) giving 50% inhibition of the control, was calculated by the method of least squares. As shown in Table 8 , karnamicin B2 exhibited activity against C. albicans vaginal infection by topical application. The activity of karnamicin B2 was slightly weaker than that of amphotericin B and about one-eighth that of nystatin.
The in vitro antibacterial activity of the components of karnamicin was determined by the serial dilution method in nutrient agar against Gram-positive and Gram-negative aerobic bacteria. The inoculum size was adjusted to 105~106 cfu/ml. The MICwas defined as the lowest concentration of test compound completely inhibiting bacterial growth after 18-hour incubation at 37°C. As shown in Table 9 , all components of karnamicin exhibited weak in vitro antibacterial activity against Grampositive bacteria, but were almost inactive against Gram-negative organisms. Karnamicin B2 was tested for in vitro anti-trichomonal activity compared with metronidazole. Table 10 shows MIC values determined after 24-hour incubation at 37°C. Karnamicin B2 exhibited appreciable activity against the clinical isolate of Trichomonasvaginalis.
Discussion
Karnamicin, a complex of antifungal antibiotics with a novel chemotype, was isolated from the cultured broth of S. aerocolonigenes No. N806-4. Chromatographic separation of the complex resulted in the isolation of 15 components, karnamicins Al9 A2, A8, Bl9 B2, B3, Cl9 C2, C3, C4, C5, D19 D2, D3 and D4, which have similar biological and chemical properties. Karnamicin components exhibited a wide spectrum of antifungal activity and weak antibacterial activity against Gram-positive bacteria. Karnamicin B2 showed in vivo efficacy against C. albicans vaginal infection by topical application. It is interesting to note that karnamicin induced morphological change of a certain mutant of C. albicans A9540. A mutant which grows only in yeast form in the presence of serum, was induced to form pseudomycelia by karnamicin components. No other antifungal and antibacterial antibiotics we tested so far caused the pseudomyceliuminduction of this mutant strain. This suggests that karnamicin has a unique mechanismof activity against fungi and yeasts.
